ABBISKO-B (02256) surged over 4% in late trading, closing up 3.9% at HK$14.13 with a turnover of HK$45.41 million. The company announced that its subsidiary, Abbisko Therapeutics, presented long-term efficacy, safety, and patient-reported outcome data from the global Phase III MANEUVER study of pimicotinib (ABSK021) for treating tenosynovial giant cell tumor (TGCT) at the Connective Tissue Oncology Society (CTOS) 2025 Annual Meeting via poster presentation. The long-term analysis demonstrated that continued treatment with pimicotinib led to sustained improvements in tumor response and further enhancements in patient-reported outcomes (including pain and function), while maintaining an acceptable safety profile. This reinforces the potential for long-term use of pimicotinib in eligible patients.